Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2020 August;111(4) > Minerva Medica 2020 August;111(4):362-4

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

SPECIAL ARTICLE   Freefree

Minerva Medica 2020 August;111(4):362-4

DOI: 10.23736/S0026-4806.20.06616-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?

Daniele SAVERINO 1, 2

1 Department of Experimental Medicine, University of Genoa, Genoa, Italy; 2 San Martino Hospital, Genoa, Italy



Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials.


KEY WORDS: COVID-19 serotherapy; COVID-19; Therapeutics

inizio pagina